| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4b2073d47e226063dd7950d434be9e0f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1426135b0402fc171a7c7a93f39e20b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02fa25ec23f1f970fd71d326afc6aa4f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8af91065d7fb31fa020c2a2576560905 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N2005-1098 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-336
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-282 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-336
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2016-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ddd4259965a383e1df8062fda8e6aa0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eec935b6986ac9710ed7883e97db6053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f22fd58b9d57a8a838ed4766a2305e9 |
| publicationDate |
2017-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017075052-A1 |
| titleOfInvention |
Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies |
| abstract |
The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of malignancies of the central nervous system in pediatric patients, including glioblastoma multiforme (GBM) high grade glioma, and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N 7 methylation and that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents (e.g. cisplatin) and can possess additive or super-additive effects. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110117293-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3589282-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019106424-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11717505-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10441654-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110117293-A |
| priorityDate |
2015-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |